Genitourinary Cancer
Philip W. Kantoff, MD
Dana-Farber Cancer Institute/Harvard Cancer Center
Leading researcher in germline and somatic genetic markers in prostate cancer
  • Kantoff is a leading researcher in germline and somatic genetic markers of prostate cancer phenotype, mechanisms of resistance to hormone therapy, and the role of microRNAs in prostate cancer.
  • His work has led to the FDA approval of drugs for prostate cancer including the chemotherapies mitoxantrone and cabazitaxel and the vaccine sipuleucel-T.
  • Kantoff played a vital role in the development of abiraterone and cabozantinib.
  • He is chief clinical research officer and chief of the Division of Solid Tumor Oncology at Dana-Farber Cancer Institute.
  • He is the leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program, and director of the prostate cancer SPORE.
  • Kantoff is the director of the Lank Center for Genitourinary Oncology, and chair of the Executive Committee for Clinical Research.
Program Information:
Previous Inductees:
2013 | 2014
2015 | 2016
2017 | 2018
2019 | 2020